Alois Hopf, CSO of Bottneuro, is representing Bottneuro AG at the LSIUSA24 in Dana Point, California. He will give some insights into Bottneuro and the next steps in our development!

He is looking forward to discuss the future of personalized neuromodulation and it's promising applications in various neurological and psychiatric disease, particularly Alzheimer's Disease and Dementia.

The first clinical trial is running right now and results will be analyzed soon. This is an important milestone for Bottneuro and will accelerate the clinical development towards a FDA cleared therapy and the market entry of the custom-made Miamind® Neurostimulator.

Thanks to all our partners at DART Ventures, Zühlke Group, HEMEX, Venture Kick, kickfund and more for taking this path with us! Excited for the years to come!